Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
The Journal of Hospital Infection
|
June 25, 2021
Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy
W Mazzucco, V Chiara di Maio, F Bronte, et al.
Journal of Neurology
|
July 22, 2021
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration
D Ferraro, P Iaffaldano, T Guerra, et al.
Cancer Chemotherapy and Pharmacology
|
June 24, 2016
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
D Ferraro, D Goldstein, R L O'Connell, et al.
European Journal of Neurology
|
October 10, 2018
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
J Lorscheider, J Kuhle, G Izquierdo, et al.
Journal of the Neurological Sciences
|
April 10, 2021
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia
D Ferraro, P Annovazzi, R Lanzillo, et al.
Multiple Sclerosis and Related Disorders
|
December 1, 2024
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study
K Smolik, F Camilli, I Panzera, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 3, 2020
Informing MS patients on treatment options: a consensus on the process of consent taking
C Tortorella, C Solaro, P Annovazzi, et al.
The British Journal of Surgery
|
April 8, 2020
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study
A L Moekotte, G Malleo, S van Roessel, et al.
Journal of Medical Economics
|
December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
T Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology
|
May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
M Lefort, S Sharmin, J B Andersen, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
The Journal of Hospital Infection
|
June 25, 2021
Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy
W Mazzucco, V Chiara di Maio, F Bronte, et al.
Journal of Neurology
|
July 22, 2021
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration
D Ferraro, P Iaffaldano, T Guerra, et al.
Cancer Chemotherapy and Pharmacology
|
June 24, 2016
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer
D Ferraro, D Goldstein, R L O'Connell, et al.
European Journal of Neurology
|
October 10, 2018
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
J Lorscheider, J Kuhle, G Izquierdo, et al.
Journal of the Neurological Sciences
|
April 10, 2021
A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia
D Ferraro, P Annovazzi, R Lanzillo, et al.
Multiple Sclerosis and Related Disorders
|
December 1, 2024
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study
K Smolik, F Camilli, I Panzera, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
April 3, 2020
Informing MS patients on treatment options: a consensus on the process of consent taking
C Tortorella, C Solaro, P Annovazzi, et al.
The British Journal of Surgery
|
April 8, 2020
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study
A L Moekotte, G Malleo, S van Roessel, et al.
Journal of Medical Economics
|
December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
T Spelman, W L Herring, C Acosta, et al.
BMC Medical Research Methodology
|
May 31, 2022
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
M Lefort, S Sharmin, J B Andersen, et al.
Page
of 8